Literature DB >> 14747959

Risk of second primary cancer following differentiated thyroid cancer.

Emmanuelle Berthe1, Michel Henry-Amar, Jean-Jacques Michels, Jean-Pierre Rame, Pascaline Berthet, Emmanuel Babin, Philippe Icard, Guy Samama, Françoise Galateau-Sallé, Jacques Mahoudeau, Stéphane Bardet.   

Abstract

Concerns remain over the risk of cancer following differentiated thyroid carcinoma and its causes. Iodine-131 ((131)I) and external irradiation are known to have potential carcinogenic effects. Thyroid carcinoma is a polygenic disease which may be associated with other malignancies. We investigated the incidence of second cancer and its aetiology in a cohort of 875 patients (146 men, 729 women) with differentiated thyroid carcinoma originating from Basse-Normandie, France. Cancer incidence was compared with that of the general population of the Département du Calvados matched for age, gender and period. The cumulative proportion of second cancer was estimated using the life-table method. Factors that correlated with the risk of second cancer were studied using the Cox model. After a median follow-up of 8 years, 58 second cancers had been observed. Compared with general population incidence rates, there was an overall increased risk of second cancer in women [standardised incidence ratio (SIR)=1.52; P<0.01], but not in men (SIR=1.27; P>0.20). Increased risk related to cancers of the genitourinary tract (SIR=3.31; P<0.001), and particularly to cancer of the kidney (SIR=7.02; P<0.01). Multivariate analysis showed that age above 40 years (P<0.01) and a history of previous primary cancer (P<0.001) correlated with risk. In contrast, neither cervical irradiation nor cumulative activity of (131)I was related to the risk. These data confirm that women with differentiated thyroid carcinoma are at risk of developing a second cancer of the genitourinary tract and kidney. Only age and medical history of primary cancer before thyroid carcinoma are risk factors for second cancer. Common environmental or genetic factors as well as long-term carcinogenic effects of primary cancer therapy should be considered.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747959     DOI: 10.1007/s00259-003-1448-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  18 in total

Review 1.  Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; R T Kloos
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

2.  Familial papillary thyroid microcarcinoma: a new clinical entity.

Authors:  G Lupoli; G Vitale; M Caraglia; M R Fittipaldi; A Abbruzzese; P Tagliaferri; A R Bianco
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

3.  Second primary tumors following thyroid cancer. A Swedish record-linkage study.

Authors:  P Hall; L E Holm; G Lundell
Journal:  Acta Oncol       Date:  1990       Impact factor: 4.089

Review 4.  The use of radioactive iodine in patients with papillary and follicular thyroid cancer.

Authors:  L Wartofsky; S I Sherman; J Gopal; M Schlumberger; I D Hay
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

Review 5.  Papillary and follicular thyroid carcinoma.

Authors:  M J Schlumberger
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

Review 6.  Familial adenomatous polyposis.

Authors:  G Lal; S Gallinger
Journal:  Semin Surg Oncol       Date:  2000-06

7.  Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study.

Authors:  T Pal; F D Vogl; P O Chappuis; R Tsang; J Brierley; H Renard; K Sanders; T Kantemiroff; S Bagha; D E Goldgar; S A Narod; W D Foulkes
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

8.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.

Authors:  M E Dottorini; G Lomuscio; L Mazzucchelli; A Vignati; L Colombo
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

9.  Leukaemias and cancers following iodine-131 administration for thyroid cancer.

Authors:  F de Vathaire; M Schlumberger; M J Delisle; C Francese; C Challeton; E de la Genardiére; F Meunier; C Parmentier; C Hill; H Sancho-Garnier
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Second primary malignancies in thyroid cancer patients.

Authors:  C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

View more
  22 in total

1.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

2.  Clinical presentations of thyroid cancer patients with multiple primary cancers.

Authors:  J D Lin; K J Lin; T C Chao; C Hseuh; N M Tsang; B Y Huang
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

3.  Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.

Authors:  Katie S Murray; Emily C Zabor; Massimiliano Spaliviero; Paul Russo; Wassim M Bazzi; John E Musser; A Ari Hakimi; Melanie L Bernstein; Guido Dalbagni; Jonathan A Coleman; Helena Furberg
Journal:  World J Urol       Date:  2016-04-22       Impact factor: 4.226

Review 4.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

Review 5.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

6.  Risk of second malignancies among survivors of pediatric thyroid cancer.

Authors:  Marwan H Adly; Mohamed Sobhy; Mohamed A Rezk; Medhat Ishak; Mahmoud A Afifi; Ayman El Shafie; Mahmoud Ahmed Ali; Wael Zekri; Ahmad Samir Alfaar; Wafaa M Rashed
Journal:  Int J Clin Oncol       Date:  2018-02-28       Impact factor: 3.402

Review 7.  Thyroid dysfunction and kidney disease: An update.

Authors:  Pedro Iglesias; María Auxiliadora Bajo; Rafael Selgas; Juan José Díez
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 8.  Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Authors:  Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins
Journal:  Eur Thyroid J       Date:  2017-03-23

9.  Adrenal morpho-functional alterations in patients with acromegaly.

Authors:  C Scaroni; R Selice; S Benedini; E De Menis; M Arosio; C Ronchi; M Gasperi; L Manetti; G Arnaldi; B Polenta; M Boscaro; N Albiger; E Martino; F Mantero
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

10.  Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer.

Authors:  Tommi T Hakala; Juhani A Sand; Arja Jukkola; Heini S Huhtala; Saara Metso; Pirkko-Liisa Kellokumpu-Lehtinen
Journal:  Int J Clin Oncol       Date:  2015-09-26       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.